Comments on FDA plan to withdraw approval of all LABAs

Long acting beta-adrenoceptor agonists (LABAs) are usually prescribed for moderate to severe persistent asthma patients or patients with COPD.

See below some Twitter responses to the news that the FDA is planning to withdraw the approval of all LABAs. The updates are in a chronological order (oldest post at the top, newest post at the bottom of the page):

Ves Dimov, M.D.
AllergyNotes FDA recommended withdrawing the approval of all LABAs? http://www.reuters.com/arti...


wheezemd
wheezemd @AllergyNotes This could be a disaster in the treatment of asthma, especially for moderate to severe children.


Ves Dimov, M.D.
AllergyNotes @wheezemd Banning LABAs "could be a disaster in the treatment of asthma, especially for moderate to severe children" -- Agree.


wheezemd
wheezemd FDA meets on LABAs this week. The question is can we prevent the FDA from banning LABAs in children.


wheezemd
wheezemd Many children with severe asthma respond to ICSs with LABAs. Do we go back to theophylline? Will we see more children hospitalized?


Follow new responses on Twitter Search.

References:

FDA sees asthma drug risks. Reuters.
The Lowdown on LABA's at Dr. Mintz' Blog
Image source: Fluticasone/salmeterol Diskus device, Wikipedia, public domain.

Related:

FDA Panel Considers Risks Of Asthma Drugs. NPR.
Update from Thorax 2012: Clearing the air: LABA/ICS reduce asthma hospitalizations, not associated with life-threatening events and deaths http://goo.gl/TesRp

No comments:

Post a Comment

Blog Widget by LinkWithin